Evidence map›Paper›PMID 36621777›Full record

Trial reportTransfusion2023

Plasma transfusion-transmission of Zika virus in mice and macaques.

Koen K A Van Rompay, Lark L Coffey, JoAnn L Yee, Anil Singapuri, Jackson Stuart, Marion C Lanteri, Felicia Santa Maria, Kai Lu, Inderdeep Singh, Sonia Bakkour and 5 more

Open access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Transfusion, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Koen K A Van RompayCalifornia National Primate Research Center, University of California, Davis, California, USA.
Lark L CoffeyDepartment of Pathology, Microbiology and Immunology, University of California, Davis, California, USA.
JoAnn L YeeCalifornia National Primate Research Center, University of California, Davis, California, USA.
Anil SingapuriDepartment of Pathology, Microbiology and Immunology, University of California, Davis, California, USA.
Jackson StuartDepartment of Pathology, Microbiology and Immunology, University of California, Davis, California, USA.
Marion C LanteriCerus Corporation, Concord, California, USA.ORCID 0000-0002-4213-5013
Felicia Santa MariaCerus Corporation, Concord, California, USA.
Kai LuVitalant Research Institute, San Francisco, California, USA.
Inderdeep SinghVitalant Research Institute, San Francisco, California, USA.
Sonia BakkourVitalant Research Institute, San Francisco, California, USA.ORCID 0000-0001-8773-0740
Mars StoneVitalant Research Institute, San Francisco, California, USA.
Phillip C WilliamsonCreative Testing Solutions, Tempe, Arizona, USA.
Marcus O MuenchVitalant Research Institute, San Francisco, California, USA.ORCID 0000-0001-8946-6605
Michael P BuschVitalant Research Institute, San Francisco, California, USA.
Graham SimmonsVitalant Research Institute, San Francisco, California, USA.ORCID 0000-0002-9615-7023
University of California, Davis · USUniversity of California, San Francisco · USPacific Research Institute · USCerus (United States) · US

Funding

National Institute on Aging (NIA) ColonyP51OD011107 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Simon J. Atkinson · 2012 to 2026
$191.5M
NHLBI NIH HHS HHSN268201100001INIH HHS P51 OD011107WHI NIH HHS HHSN268201100001C
6 · The paper itself

Abstract

backgroundZika virus (ZIKV) epidemics with infections in pregnant women are associated with severe neurological disease in newborns. Although an arbovirus, ZIKV is also blood transfusion-transmitted (TT). Greater knowledge of the efficiency of ZIKV TT would aid decisions on testing and pathogen reduction technologies (PRT). STUDY DESIGN AND

methodsPlasma units from ZIKV RNA-reactive blood donors were used to study infectivity in vitro, in mice, and in macaques. Furthermore, plasma units were subjected to PRT using amotosalen/ultraviolet light A (A/UVA) before transfusion.

resultsIn vitro infectivity of ZIKV RNA-reactive plasma varied between 100 and 1000 international units (IU) of ZIKV RNA. Immunodeficient mice were more sensitive with as low as 32 IU sufficient to infect 50% of mice. 50-5500 IU of RNA led to TT in macaques using dose escalation of three different RNA-positive, seronegative plasma units. In contrast, RNA-reactive units collected postseroconversion were not infectious in macaques, even at a dose of 9 million IU RNA. After A/UVA PRT, transfusion of plasma containing up to 18 million IU was no longer infectious in vitro and did not result in ZIKV TT in macaques.

conclusionSignificant risks of ZIKV TT are likely confined to a relatively short viremic window before seroconversion, and that sensitive nucleic acid amplification testing likely identifies the majority of infectious plasma. PRT was demonstrated to be effective at preventing ZIKV TT. Considering that there is no approved ZIKV vaccine, these data are relevant to mitigate the risk of TT during the future ZIKV outbreaks.

Indexed as

Zika VirusZika Virus InfectionAnimalsBlood Component TransfusionBlood TransfusionFemaleHumansMicePlasmaPregnancyRNA, ViralRNA, ViralInfectious disease testingpathogen reductiontransfusion-transmitted disease

Identifiers

PMID36621777
PMCPMC10134791
OpenAlexW4313825760

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.